Swedish Orphan Biovitrum Overview

  • Founded
  • 2001
Founded
  • Status
  • Public
  • Employees
  • 1,568
Employees
  • Stock Symbol
  • SOBI
Stock Symbol
  • Investments
  • 7
  • Share Price
  • $16.87
  • (As of Wednesday Closing)

Swedish Orphan Biovitrum General Information

Description

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum also acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched its hemophilia products Alprolix and Eloctate in Europe in 2016. In 2019, Sobi acquired rights to rare disease drug Gamifant, U.S. rights to Astra's RSV prevention drug Synagis, and rights to thrombocytopenia drug Doptelet (with the Dova acquisition). In 2020, new collaborations brought rights to gout drug pegadricase and complement-mediated disease drug pegcetacoplan.

Contact Information

Website
Formerly Known As
Biovitrum
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
STO
Primary Office
  • Tomtebodavägen 23A
  • Solna
  • 112 76 Stockholm
  • Sweden
+46 08-697 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Swedish Orphan Biovitrum Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.87 $16.50 $15.51 - $27.00 $4.98B 295M 911K $1.19

Swedish Orphan Biovitrum Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 7,437,000 7,437,000 5,675,997 5,515,685
Revenue 1,655,156 1,655,156 1,506,387 1,050,334
EBITDA 725,900 725,900 641,970 416,042
Net Income 351,942 351,942 349,319 277,898
Total Assets 5,885,960 5,885,960 4,883,397 1,911,610
Total Debt 1,776,284 1,776,284 1,771,191 445
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Swedish Orphan Biovitrum Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Swedish Orphan Biovitrum‘s full profile, request access.

Request a free trial

Swedish Orphan Biovitrum Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started w
Biotechnology
Stockholm, Sweden
1,568 As of 2020
000.00
0.00 0000-00-00
000000&0

00000000

consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut e
0000 000000000
Zurich, Switzerland
000 As of 0000
00000
0000 0000-00-00
000000000 00000

000000

ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dol
0000 000000000
Cambridge, MA
0000 As of 0000
000.00
00000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Swedish Orphan Biovitrum Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Molecular Partners Formerly VC-backed Zurich, Switzerland 000 00000 000000000 00000
000000 Formerly VC-backed Cambridge, MA 0000 000.00 00000000000 000.00
00000 Formerly PE-Backed Thousand Oaks, CA 00000 00.000 000000000000 00.000
000000 Corporation Smyrna, GA 0 000.00 00000000 000.00
000000 00000000 Formerly VC-backed Foster City, CA 00000 00.000 000000&0
You’re viewing 5 of 13 competitors. Get the full list »

Swedish Orphan Biovitrum Executive Team (30)

Name Title Board Seat Contact Info
Guido Oelkers Chief Executive Officer & President
Henrik Stenqvist Chief Financial Officer
Maria Kruse Director Corporate Communication and Investor Relations
Fredrik Berg General Counsel
Paula Treutiger Head of Communications & Investor Relations and Senior Vice President
You’re viewing 5 of 30 executive team members. Get the full list »

Swedish Orphan Biovitrum Board Members (4)

Name Representing Role Since
00000 00é0 Self Board Member 000 0000
0å000 00ö000000 00.0 Swedish Orphan Biovitrum Chairman 000 0000
You’re viewing 2 of 4 board members. Get the full list »

Swedish Orphan Biovitrum Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Swedish Orphan Biovitrum Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Swedish Orphan Biovitrum‘s full profile, request access.

Request a free trial

Swedish Orphan Biovitrum Investments & Acquisitions (7)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
0000000 0000000000 11-Jun-2020 0000 0000 Drug Discovery 00000 0000000
0000 0000000000000 12-Nov-2019 000000000000000000 00000 Pharmaceuticals 00000 0000000
000000000 (000000 18-Jul-2019 000000000 00000 00 00000 Buildings and Property 00000 0000000
0000000 (0.0. 0000 24-Jan-2019 000000000 00000 00 00.000 Buildings and Property 00000 0000000
Amgen (Rights to Kineret - Anakinra) 09-Sep-2013 Corporate Asset Purchase Buildings and Property 00000000 000000000 00
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Swedish Orphan Biovitrum Subsidiaries (3)

Company Name Industry Location Founded
Dova Pharmaceuticals Pharmaceuticals Durham, NC 2016
000000000 Drug Discovery Stockholm, Sweden 0000
0000000 (0.0. 0000 Buildings and Property WALTHAM, MA
To view Swedish Orphan Biovitrum’s complete subsidiaries history, request access »